No profile data available.
Rhythm Pharmaceuticals, Inc. (RYTM) is a healthcare company in the obesity treatment pharmaceuticals industry, based in Boston, United States, with about 414 full-time employees.
It reported revenue of $189.76 million for fiscal year 2025, up 45.8% from fiscal year 2024, and net income of -$201.92 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $71.26 million, up 46.9% from a year before. United States was its largest region in fiscal year 2025, with 69% of revenue. Its market capitalization was $6.23 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
Rhythm Pharmaceuticals reported $189.76 million in revenue for fiscal year 2025, up 45.8% from $130.13 million in fiscal year 2024. In Q2 2026 revenue was $71.26 million.
United States: 69% of revenue by region in fiscal year 2025, followed by International (31%).
$6.23 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (obesity treatment pharmaceuticals) include Metsera, Inc. (MTSR), Structure Therapeutics Inc. (GPCR), BioAge Labs, Inc. (BIOA), Aardvark Therapeutics, Inc. (AARD).